OCS Liver PROTECT Continuation Post-Approval Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- University of California San Diego
-
San Diego, California, United States, 92121
- Scripps
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Florida
-
Tampa, Florida, United States, 33606
- Tampa General
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- EMORY
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Medical Center
-
-
Tennessee
-
Memphis, Tennessee, United States, 38104
- University of Tennessee Health Science Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- University of Texas Southwest
-
Houston, Texas, United States, 77030
- Houston Methodist Hospital
-
San Antonio, Texas, United States, 78229
- The University of Texas Health Science Center at San Antonio
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University Health System
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects transplanted in the OCS Liver PROTECT Trial
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Control
|
|
|
OCS Liver
|
Transplanted with a OCS preserved liver
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver Graft Survival
Time Frame: 2 years
|
Liver Graft Survival through 2 years (24 months) after transplantation.
|
2 years
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Survival
Time Frame: 2 years
|
Patient Survival (freedom from mortality) through 2 years (24 months) after transplantation.
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- OCS-LVR-01-PAS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.